Literature DB >> 11551527

Increase in hepatic expression of SREBP-2 by gemfibrozil administration to rats.

N Roglans1, C Peris, J C Verd, M Alegret, M Vázquez, R M Sánchez, J C Laguna.   

Abstract

It is well known that gemfibrozil increases the biliary output of cholesterol and phospholipids, but we have little knowledge about the impact these changes have on liver cholesterol and phospholipid biosynthetic pathways. In the present study, no changes were detected in liver lipids and CTP:phosphocholine cytidylyltransferase after gemfibrozil administration to rats. On the contrary, 3-hydroxy-3-methylglutaryl-CoA reductase mRNA (9.9-fold) and Rd activity (16.7-fold) and phosphatidate phosphohydrolase activity (1.7-fold) increased, while plasma apo B-cholesterol (40%) and triglyceride (43%) levels decreased. As a part of a compensatory homeostatic response, we report for the first time that gemfibrozil administration to rats increased the hepatic sterol regulatory element binding protein-2 (SREBP-2) mRNA (2.9-fold) and mature protein (2.2-fold) levels. An early increase in the transcriptional activity of SREBP-2 elicited by gemfibrozil administration might be responsible for the observed changes in HMG-CoA reductase, phosphatidate phosphohydrolase, and SREBP-2 expression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11551527     DOI: 10.1016/s0006-2952(01)00701-8

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  5 in total

1.  Peroxisome deficiency-induced ER stress and SREBP-2 pathway activation in the liver of newborn PEX2 knock-out mice.

Authors:  Werner J Kovacs; Khanichi N Charles; Katharina M Walter; Janis E Shackelford; Thomas M Wikander; Michael J Richards; Steven J Fliesler; Skaidrite K Krisans; Phyllis L Faust
Journal:  Biochim Biophys Acta       Date:  2012-03-13

2.  Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients.

Authors:  Núria Roglans; Manuel Vázquez-Carrera; Marta Alegret; Ferran Novell; Daniel Zambón; Emilio Ros; Juan C Laguna; Rosa M Sánchez
Journal:  Eur J Clin Pharmacol       Date:  2003-12-18       Impact factor: 2.953

Review 3.  Role of fibric acid derivatives in the management of risk factors for coronary heart disease.

Authors:  Jean-Pierre Després; Isabelle Lemieux; Sander J Robins
Journal:  Drugs       Date:  2004       Impact factor: 9.546

4.  High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production.

Authors:  Núria Roglans; Joan C Verd; Cristina Peris; Marta Alegret; Manuel Vázquez; Tomás Adzet; Cristina Díaz; Gonzalo Hernández; Juan C Laguna; Rosa M Sánchez
Journal:  Lipids       Date:  2002-05       Impact factor: 1.880

5.  Effects of Tanshinone IIA on the modulation of miR‑33a and the SREBP‑2/Pcsk9 signaling pathway in hyperlipidemic rats.

Authors:  Lianqun Jia; Nan Song; Guanlin Yang; Yixin Ma; Xuetao Li; Ren Lu; Huimin Cao; Ni Zhang; Meilin Zhu; Junyan Wang; Xue Leng; Yuan Cao; Ying Du; Yue Xu
Journal:  Mol Med Rep       Date:  2016-04-14       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.